Biotechnology

Positive Phase 1b data for two novel drugs suggests a long-acting, once-monthly oral therapy for recurrent genital herpes may be on the horizon.

As drug-resistant superbugs threaten modern medicine, a novel liquid therapeutic from Seres Therapeutics offers a lifeline for the most vulnerable patients.

Behavior Labs launches a new platform to close the life sciences' 'ground truth gap,' replacing slow quarterly reviews with continuous, daily intelligence.

With Christoph Korpus at the helm, Byondis signals a strategic shift to accelerate its innovative cancer therapies through new partnerships and commercialization.

With Nuvaxovid set for a 2026 rollout, Sanofi aims to address vaccine hesitancy and expand choices as Canada continues to battle the virus.

China's Gan & Lee partners with JW Pharmaceutical to launch its novel bi-weekly GLP-1 drug, Bofanglutide, into the competitive South Korean market.

With a personal family connection to type 1 diabetes and a £100M war chest, Anastasia Bukhman joins the T1D Fund's board to speed up research.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

New Medicare billing codes for the biosimilar Tyenne are now in effect, simplifying reimbursement and aiming to improve access for severe COVID-19 patients.

With its European trial launch, Kainova's DT-7012 aims to disarm cancer's bodyguards, offering new hope for patients with advanced solid tumors.

With the hire of a top scientist, a minority-owned IT firm signals its ambition to tackle complex federal health challenges and compete with industry giants.

OncoC4 begins a landmark trial for ONC-841, a drug targeting immune cells in the brain, offering a new front in the fight against Alzheimer's disease.

AllRock Bio has begun a Phase 2a trial for its novel drug ROC-101, testing it in combination with new standard-of-care therapies for pulmonary hypertension.

A Swiss biotech's novel antibiotic has entered human trials with new funding, offering a fresh hope against the world's most dangerous superbugs.

Satri-cel, the world's first CAR-T therapy for solid tumors, is set to launch in China, offering a powerful new weapon against advanced stomach cancers.

Aptar Digital Health and Enable Injections are pairing the enFuse® wearable injector with a new digital app to transform self-care for chronic diseases.

As Option Care Health preps its Q1 results, investors watch if it can seize market share from a retreating rival while navigating major biosimilar headwinds.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

A single-dose therapy wiped out aggressive glioblastoma tumors in a landmark pre-clinical study, paving the way for human trials in 2026.